Work

Children's Oncology Group's 2013 blueprint for research: Bone tumors

Year: 2012

Type: review

Abstract: In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.24429

Authors: Richard Gorlick, Katherine Janeway, Stephen Lessnick, R. Lor Randall, Neyssa Marina